Mayne Pharma Q1 FY24 Trading Update
Mayne Pharma CEO Shawn Patrick O’Brien said: “We are very pleased to report the progress of Mayne Pharma as we continue our transition phase and simplify our business. The first quarter of FY24 reflects the hard work undertaken to improve operating performance and drive revenue and margin. Our team are engaged to deliver on the potential of our portfolio in the markets we operate in.”
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Mayne Pharma Group Limited a question about this update.